About Hana Pharm
Hana Pharm is a publicly listed company based in Seoul (South Korea) founded in 1996. It operates as a general anesthetics and therapies for chronic diseases are developed. The company has 730 employees. Its chief executive is Younha Lee. Its website hanaph.co.kr draws about 382 thousand monthly visits. Its focus areas include Life Sciences, Pain Management, Drugs and Diversified. Its competitors include Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Hana Pharm was founded in 1996 in Seoul, South Korea, and operates in the pharmaceutical sector. General anesthetics are developed, with the lead candidate HNP-2001 (remimazolam) targeting GABA receptors for sedative and hypnotic effects during phase III clinical trials. Additional therapies are pursued for conditions including Alzheimers disease, diabetic retinopathy, and non-alcoholic steatohepatitis.
- Headquarters Seoul, South Korea
- Employees 730
- Stage Public
- SectorsHealthcare
- Website category Health · Medicine
- Phone•••• ••••
- Website hanaph.co.kr/index.do
- Legal Name Hana Pharm Co., Ltd.
- Annual Revenue$165.84 M (USD)6.29as on Dec 31, 2025
- Net Profit$6.08 M (USD)-58.69as on Dec 31, 2025
- EBITDA$25.59 M (USD)12.86as on Dec 31, 2025
- Employee Count730
People of Hana Pharm
1 people are tracked at Hana Pharm (1 in leadership); the tracked headcount is 730.
| Name | Role | Group |
|---|---|---|
Younha Lee | CEO | Leadership |
Complete people profiles for Hana Pharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hana Pharm
Hana Pharm is a publicly listed company on the KRX with ticker symbol 293480 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Sep 2018
- Listed onKRX: 293480
- Listed entityHana Pharm Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7293480000
- Share price8,350.00 KRW (+0.48% on the day) · 2026-10-14
- Market capitalisation143,758,729,992.00 KRW
- Price to earnings8.5
- EPS (diluted, trailing year)984.08 KRW
- Dividend yield3.13%
- Volume (last session)10,540
Financials of Hana Pharm
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 239.50B KRW | 8.78B KRW | 36.95B KRW |
| 2024 | 225.34B KRW | 21.25B KRW | 32.74B KRW |
| 2023 | 224.46B KRW | 22.33B KRW | 33.71B KRW |
| 2022 | 210.84B KRW | 24.31B KRW | 37.49B KRW |
| 2021 | 196.41B KRW | 28.01B KRW | 41.67B KRW |
Detailed financial statements for Hana Pharm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Hana Pharm
Hana Pharm has 10 listed competitors in our database, 9 of them funded. They include Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. | |
| herontx.com | 1983 | Redwood, United States | – | 21 | Reformulated injectables for chemotherapy side effects and pain are developed. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| egalet.com | 1995 | Vaerlose, Denmark | $70.88M | 1 | Therapeutics for pain management are developed with abuse-deterrent designs. | |
| painreform.com | 2007 | Herzliya, Israel | $12M | – | Pain treatment products are developed through reformulation technologies. | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| concentricanalgesics.com | 2014 | San Francisco, United States | $85.46M | – | Developer of platform for developing pro-drugs | |
| satsumarx.com | 2016 | San Francisco, United States | $74.13M | 24 | Therapeutics for migraine treatment are developed using nasal delivery. |
Detailed competitors of Hana Pharm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hana Pharm
The website of Hana Pharm (hanaph.co.kr) receives about 381.7K visits a month and ranks #157,959 among all websites worldwide, #4,932 in Medicine.
- Monthly visits381.7K
▲ 49.2% vs previous month
- Unique visitors48.2K
per month
- Global rank#157,959
among all websites
- Category rank#4,932
Health · Medicine
- Bounce rate48%
- Pages per visit5.7
- Average visit4 min 17 sec
- DevicesDesktop 10% · Mobile 90%
Websites whose visitors overlap most with Hana Pharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
eonelab.co.kr | eonelab.co.kr | 100% | – | – | – |
jkma.org | jkma.org | 88% | – | #1,520,672 | – |
dailypharm.com | dailypharm.com | 85% | – | #33,384 | – |
yakup.com | yakup.com | 85% | – | #118,603 | – |
| health.kr | 85% | – | #14,868 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Hana Pharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pain Management
10 companies that operate in the same segment as Hana Pharm (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hana Pharm
Complete news archive for Hana Pharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hana Pharm
Hana Pharm was founded in 1996.
Hana Pharm is headquartered in Seoul, South Korea.
Younha Lee is the current CEO of Hana Pharm.
Hana Pharm has 730 employees.
Annual revenue of Hana Pharm is $165.84M as on Dec 31, 2025.
Hana Pharm was founded in 1996 in Seoul, South Korea, and operates in the pharmaceutical sector. General anesthetics are developed, with the lead candidate HNP-2001 (remimazolam) targeting GABA receptors for sedative and hypnotic effects during phase III clinical trials. Additional therapies are pursued for conditions including Alzheimers disease, diabetic retinopathy, and non-alcoholic steatohepatitis.
Hana Pharm's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Yes, Hana Pharm is publicly traded on KRX under the ticker symbol 293480.
The website of Hana Pharm receives about 382 thousand visits a month and ranks #157,959 among all websites worldwide.